445 related articles for article (PubMed ID: 26177893)
1. Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism.
Kim ES; Keating GM
Drugs; 2015 Jul; 75(11):1293-303. PubMed ID: 26177893
[TBL] [Abstract][Full Text] [Related]
2. Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.
Marcucci G; Della Pepa G; Brandi ML
Expert Opin Drug Saf; 2017 May; 16(5):617-625. PubMed ID: 28332412
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
[TBL] [Abstract][Full Text] [Related]
4. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
Clarke BL; Vokes TJ; Bilezikian JP; Shoback DM; Lagast H; Mannstadt M
Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
6. AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
Lakatos P; Bajnok L; Lagast H; Valkusz Z
Endocr Pract; 2016 May; 22(5):523-32. PubMed ID: 26684150
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human parathyroid hormone (1-84) replacement therapy in a child with hypoparathyroidism.
Laurer E; Grünberger J; Naidoo U; Lanzersdorfer R; Wimleitner M; Tischlinger K; Högler W
Bone; 2021 Mar; 144():115834. PubMed ID: 33359892
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide.
Puig-Domingo M; Díaz G; Nicolau J; Fernández C; Rueda S; Halperin I
Eur J Endocrinol; 2008 Nov; 159(5):653-7. PubMed ID: 18703565
[TBL] [Abstract][Full Text] [Related]
9. Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety.
Tay YD; Tabacco G; Cusano NE; Williams J; Omeragic B; Majeed R; Gomez Almonte M; Bilezikian JP; Rubin MR
J Clin Endocrinol Metab; 2019 Nov; 104(11):5601-5610. PubMed ID: 31310310
[TBL] [Abstract][Full Text] [Related]
10. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.
Rubin MR; Cusano NE; Fan WW; Delgado Y; Zhang C; Costa AG; Cremers S; Dworakowski E; Bilezikian JP
J Clin Endocrinol Metab; 2016 Jul; 101(7):2742-50. PubMed ID: 27144931
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.
Mannstadt M; Clarke BL; Bilezikian JP; Bone H; Denham D; Levine MA; Peacock M; Rothman J; Shoback DM; Warren ML; Watts NB; Lee HM; Sherry N; Vokes TJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5136-5147. PubMed ID: 31369089
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-μg or 50-μg Daily Doses.
Bilezikian JP; Clarke BL; Mannstadt M; Rothman J; Vokes T; Lee HM; Krasner A
Clin Ther; 2017 Oct; 39(10):2096-2102. PubMed ID: 28942334
[TBL] [Abstract][Full Text] [Related]
13. A New Era for Chronic Management of Hypoparathyroidism: Parathyroid Hormone Peptides.
Marcucci G; Brandi ML
Front Horm Res; 2019; 51():165-171. PubMed ID: 30641529
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hypoparathyroidism.
Tecilazich F; Formenti AM; Frara S; Giubbini R; Giustina A
Best Pract Res Clin Endocrinol Metab; 2018 Dec; 32(6):955-964. PubMed ID: 30551988
[TBL] [Abstract][Full Text] [Related]
15. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
Sikjaer T; Amstrup AK; Rolighed L; Kjaer SG; Mosekilde L; Rejnmark L
J Bone Miner Res; 2013 Oct; 28(10):2232-43. PubMed ID: 23649554
[TBL] [Abstract][Full Text] [Related]
16. Management of Hypoparathyroidism: Present and Future.
Bilezikian JP; Brandi ML; Cusano NE; Mannstadt M; Rejnmark L; Rizzoli R; Rubin MR; Winer KK; Liberman UA; Potts JT
J Clin Endocrinol Metab; 2016 Jun; 101(6):2313-24. PubMed ID: 26938200
[TBL] [Abstract][Full Text] [Related]
17. Hypoparathyroidism - disease update and emerging treatments.
Monis EL; Mannstadt M
Ann Endocrinol (Paris); 2015 May; 76(2):84-8. PubMed ID: 25882889
[TBL] [Abstract][Full Text] [Related]
18. [PTH-replacement therapy in hypoparathyroidism : what benefits ?].
Trombetti A; Bégin MJ
Rev Med Suisse; 2021 Apr; 17(735):788-792. PubMed ID: 33881242
[TBL] [Abstract][Full Text] [Related]
19. Therapy of hypoparathyroidism with intact parathyroid hormone.
Rubin MR; Sliney J; McMahon DJ; Silverberg SJ; Bilezikian JP
Osteoporos Int; 2010 Nov; 21(11):1927-34. PubMed ID: 20094706
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone therapy for hypoparathyroidism.
Cusano NE; Rubin MR; Bilezikian JP
Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):47-55. PubMed ID: 25617172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
